Toronto, ON — August 28, 2025 — Leads & Copy — NurExone Biologic Inc. has released its financial results for the second quarter ended June 30, 2025, along with a corporate update. The company raised C$2.3 million through a private placement in April and outlined plans to initiate a Phase 1/2a trial of ExoPTEN for acute spinal cord injury in 2026, pending regulatory clearances, at the American Spinal Injury Association Annual Meeting on May 30, 2025.
On June 4, 2025, NurExone reported new manufacturing process validation data supporting scalability and consistency of exosome production. The company was also accepted into the Advanced Regenerative Manufacturing Institute’s HealthTech Hub Accelerator on June 20, 2025. Research and development expenses were US$0.70 million, and general and administrative expenses were US$1.13 million for the quarter. Net loss for the quarter was US$1.85 million.
NurExone is focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing potential in treating spinal cord and optic nerve injuries.
Dr. Lior Shaltiel, Chief Executive Officer and Director, can be reached at +972-52-4803034 or info@nurexone.com. Dr. Eva Reuter, Investor Relations – Germany, can be reached at +49-69-1532-5857 or e.reuter@dr-reuter.eu. Allele Capital Partners, Investor Relations – U.S., can be reached at +1 978-857-5075 or aeriksen@allelecapital.com
Source: NurExone Biologic Inc.
